At a glance
ClinicalIndex Comparison Record- ✓Histological confirmation of solid tumor or hematological malignancy, OR high-risk for cancer (cancer predisposition gene aberration or hormonal/family history)
- ✓Age ≥18 years
- ✓Signed and dated informed consent form for LIBERATE study
- ✓If co-consented to separate primary research study, must fulfill that study's eligibility criteria
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
In Brief
An observational study for Cancer and 17 related conditions. Currently recruiting, targeting 2,500 participants across 1 site.
Detailed Summary
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.